DOCSLIB.ORG

Leukemia and Lymphoma: Molecular and Therapeutic Insights

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leukemia and Lymphoma: Molecular and Therapeutic Insights This is a free sample of content from Leukemia and Lymphoma: Molecular and Therapeutic Insights. Click here for more information on how to buy the book. Index A PRPF8, 307 AA. See Aplastic anemia SF3B1, 307 ABL1, 347, 368–369 SRSF2, 307 ABL2, 369 SUZ12, 120 ABT-199, 368 TET2, 117, 119, 121, 305 ABT-731, 181 U2AF1, 307 ACIN1, 374 U2AF2, 307 Acute lymphocytic leukemia (ALL). See also B- ZRSR2, 307 progenitor acute lymphoblastic therapeutic targeting leukemia; T-cell acute lymphoblastic combination therapy, 123–124 leukemia histone epigenetic mechanisms, 121, 123 epidemiology specific epigenetic mechanisms, 121 adult, 32–33 induced pluripotent stem cell models, 257–259 pediatric, 29–30 leukemia stem cell studies. See Leukemia stem cell Acute megakaryoblastic leukemia (AMKL) model children without Down syndrome, 326–329 mouse models. See Mouse models Down syndrome association pathophysiology, 295–296 clinical and biological features, 324–325 recurrent mutations GATA1 CEBPA, 301–302 cooperation with trisomy genes, 323–324 GATA2, 302 mutations, 323 NPM1, 300–301 genetic susceptibility, 321–322 RUNX1, 301 transforming mutation acquisition, 325–326 signal transduction mutations overview, 319–320 CBL, 303 RNA-binding proteins, 153 FLT3, 302 Acute myeloid leukemia (AML) KIT, 302–303 chromosomal abnormalities KRAS, 303 core binding factor rearrangements, 296–297 NF1, 303–304 KMT2A rearrangements, 298–299 NRAS, 303 rare translocations, 299–300 PTPN11, 303 clonal hematoipoiesis, 75 therapeutic targeting epidemiology CD123, 91–92 adult, 31–32 CD33, 90 pediatric, 29–31 FLT3, 90–91 epigenetics limitations, 90 cytosine methylation profiles, 115–117 prospective leukemia stem cell targets. gene mutations See Leukemia stem cell ASXL1, 120–121, 306 tumor suppressor gene mutations BCOR, 306–307 PHF6, 308 BCORL1, 306–307 TP53, 307–308 cohesin, 307 WT1, 308 DNMT3A, 117, 304–305 ADI-PEG20, 182 EZH2, 120 Adult T-cell leukemia/lymphoma (ATLL) IDH1, 120, 305–306 clinical presentation, 473–474 IDH2, 120, 305–306 genetics, 474 LUC7L2, 307 pathogenesis, 473 507 © 2021 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Leukemia and Lymphoma: Molecular and Therapeutic Insights. Click here for more information on how to buy the book. Index AF10, 298 B-cell lymphoma. See also specific lymphomas AF4, 298 classification, 448, 451 AF9, 298, 303 genetics, 450–451 Age-related clonal hematopoiesis (ARCH), 11, 13, 73 germinal center B-cell-derived lymphomas, 451–452 AICDA, 49 lymphomagenesis, 448 AITL. See Angioimmunoblastic T-cell lymphoma post-germinal center and marginal zone B-cell- AKT, 346 derived lymphomas, 452–453 ALCL. See Anablastic large cell lymphoma pre-germinal center B-cell-derived lymphomas, 451 Alisertib, 329 B-cell maturation antigen (BCMA), 494–497 ALK, 431 BCL1. See CCND1 ALK, 55–56, 473 BCL2, 49, 152, 183, 185, 368, 396, 399 ALL. See Acute lymphocytic leukemia BCL2, 52, 54, 162, 234–236, 239, 374, 448, 452 AMKL. See Acute megakaryoblastic leukemia BCL6, 128, 236–237, 239, 242, 306 AML. See Acute myeloid leukemia BCL6, 52, 54, 374, 452 AML1, 303 BCL11B, 342, 344 AMPK, 7 BCMA. See B-cell maturation antigen Anablastic large cell lymphoma (ALCL) BCOR, 74, 306–307 clinical features, 472 BCORL1, 74, 306–307 genetics, 472–473 BCR, 368–369 genetics, 55–56, 472–473 BHLHB1, 341 overview, 187 Bioenergetics. See Metabolism, leukemia/lymphoma Angioimmunoblastic T-cell lymphoma (AITL) BIRC3, 389 epidemiology, 469 BiTEs, 495–497 genetics, 57 469–471 BL. See Burkitt lymphoma APC, 326, 471 BLCL2A1, 186 Aplastic anemia (AA), 74 BLIMP1, 241 APOBEC, 119 BMI1, 152, 161 ARAF, 425 Bortezomib, 478, 489 ARCH. See Age-related clonal hematopoiesis B-progenitor acute lymphoblastic leukemia (B-ALL) ARF, 340 chromosomal alterations ARHGEF1, 240 gross abnormalities, 364, 367 ARID1A, 51, 54, 476 translocations, 367–368 ARID1B, 475 inherited variants, 375–376 ARID1B, 471 microenvironment, 377 ARID2, 283 mixed phenotype ALL, 374–375 ARID2, 471 overview, 363–364 ARID5B, 476 prospects for study, 377–378 ASCT2, 181 relapse, 376–377 ASNS, 181 subtypes ASS1, 182 DUX4-rearranged ALL, 371 ASXL1, 70, 74, 120–121, 260, 280–281, 302, 306 ETV6-RUNX1-like ALL, 369 ATLL. See Adult T-cell leukemia/lymphoma IGH rearrangements, 374 AT M , 49, 243, 451, 454 IKZF1 N159Y, 372, 374 AT R , 128 MEF2D rearrangement, 371 AURKA, 329 novel subtypes, 368–372 NUTM1 rearrangements, 374 PAX5-driven subtypes, 372 B Ph-like ALL, 369 Bach2, 206 prevalence and prognosis, 365–366 B-ALL. See B-progenitor acute lymphoblastic leukemia ZNF384 rearrangement, 371–372 BAP1, 306 BRAF, 425, 439, 492 BAX, 186, 456 BRAF, 51, 53, 59, 421–423, 430–433, 437–440 BCAT1, 159, 184 BRD4, 281 B-cell, development, 226–227, 448–449 BRD4, 374 508 © 2021 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Leukemia and Lymphoma: Molecular and Therapeutic Insights. Click here for more information on how to buy the book. Index BRD9, 374 CFS1R, 371 Brentuximab, 456 CH. See Clonal hematoipoiesis BTK, 49, 403, 456 CHAF1B, 322 BTK,50 CHD8, 471 BTLA, 364 CHEK1, 128 Burkitt lymphoma (BL) CHIP, 276 genetics, 54 Chronic lymphocytic leukemia (CLL) mouse models, 232–233 B-cell surface receptors B-cell receptor signaling, 390–392 chemokine receptors, 392 C microenvironmental signals associated with CALR, 257, 276 clonal expansion, 392–393 CARD11, 56, 457, 476 combinatorial indices in management, 396 Carfilzomib, 488 diagnosis, 395 CBCL. See Primary cutaneous B-cell lymphoma epidemiology, 386 CBFA2T3, 328–329 genetics CBFB, 296–297 noninherited recurrent mutations, 388–390 CBL, 284 susceptibility genes, 386, 388 CBL, 70, 284–285, 303 monoclonal B-cell lymphocytosis, 393–394 CCL3, 393 normal cell equivalents, 394–395 CCL4, 393 overview, 385–386 CCND1, 50, 52, 229, 451 predictive markers in therapy, 395–396 CCND2, 341 prognostic markers, 395 CCND3, 51, 54, 233, 338, 340, 439 progression CCR4, 474, 479 aggressive clonal variant promoters, 399 CCR4,57 cell growth rate role, 400 CCR7, 474 clonal evolution, 400 CCUS. See Clonal cytopenia of undetermined Richter’s transformation, 400, 402–403 significance risk factors, 386 CD3, 348 treatment CD7, 348 anti-apoptotic protein targeting, 399 CD19, 458 chemoimmunotherapy, 398 CD200, 364 initial therapy, 396–397 CD23, 395 monoclonal antibodies, 398 CD28, 471, 474 pathway inhibitors, 398–399 CD30, 480 progression targeting, 403 CD31, 393 refractory disease, 402–403 CD33, 90 relapsed disease, 402–403 CD38, 392–393, 395, 491, 493, 497 Chronic Lymphocytic Leukemia International CD47, 479 Prognostic Index (CLL-IPI), 396 CD58, 474 Chronic lymphocytic leukemia/small cell lymphoma CD79B, 452–453 (CLL/SCL) CD123, 91–92 epidemiology, 33–34 CDK4, 232 genetics, 48–50 CDK4, 338 mouse models, 242–243 CDK6, 338 Chronic myeloid leukemia (CML) CDKN1A, 237 epidemiology, 33 CDKN1B, 237, 340, 476 induced pluripotent stem cell models, CDKN2A, 56, 337, 340, 364, 368, 375 255–256 CDKN2B, 364, 368, 375 CLL. See Chronic lymphocytic leukemia CDKN2D, 338 CLL/SCL. See Chronic lymphocytic leukemia/small CDR, 242 cell lymphoma C/EBP, 159–160 CLL-1, acute myeloid leukemia therapeutic CEBPA, 301–302 targeting, 101–102 509 © 2021 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Leukemia and Lymphoma: Molecular and Therapeutic Insights. Click here for more information on how to buy the book. Index CLL-IPI. See Chronic Lymphocytic Leukemia DEK, 299 International Prognostic Index D2HGDH, 188 Clonal cytopenia of undetermined significance DHODH, 183 (CCUS), 73–74 Diffuse large B-cell lymphoma (DLBCL) Clonal hematoipoiesis (CH) cellular origins, 228 aplastic anemia, 74 epidemiology, 37–38 bystander clonal hematoipoiesis, 75–76 epigenetics clonal cytopenia of undetermined significance, cytosine methylation patterning, 130 73–74 gene mutations in epigenetic modifiers, founder clonal hematoipoiesis and leukemia 128–130 progression, 74–75 immune synapse as focal point for epigenetic genetic susceptibility, 77 dysregulation in lymphoma, 130 hematologic malignancy risk, 71 overview, 124–128 idiopathic cytopenia of undetermined significance, therapeutic targeting 73–74 nonspecific therapies, 130, 132 interventions precision therapy, 132–133 follow-up, 78 genetics, 52–54, 451–452 inflammation inhibition, 78 heterogeneity, 460–461 metformin, 78 mouse models mutation targeting, 77 BCL6 dysregulation, 239 preclinical studies, 77 FBXO11 deletion, 240 vitamin C, 77–78 Ga13 pathway disruption, 240 multiple myeloma outcomes, 76 NF-kB signaling activation, 241–242 mutation landscape, 70–71 PRDM1/BLIMP1, 241 overview, 69–70 DLBCL. See Diffuse large B-cell lymphoma prospects for study, 78–79 DLEU2, 242 solid tumor outcomes, 76 DLEU7, 242 technical definition, 71–73 DNA methyltransferase. See also Epigenetics CML. See Chronic myeloid leukemia acute myeloid leukemia inhibitor therapy, 124 CNOT3, 348 DNMT1, 279 Cohesin, 214, 255, 307 DNAMT3A, 13–14, 57, 70, 74–75, 77–78, 85, CPI-613, 180 117, 206, 210–211, 260, 279–280, CREBBP, 234–237 304–305, 319, 469, 476 CREBBP, 52, 53, 128–130, 364, 452, 471 DOT1L, 298–299 CRISPR–Cas9, 204–205, 244, 255, 258, 460 Down syndrome Crizotinib, 479 acute megakaryoblastic leukemia CRLF2, 367, 369, 374 clinical and biological features, 324–325 CSF1R, 432 GATA1 CTCF, 214, 329 cooperation with trisomy genes, 323–324 CTCF, 329 mutations, 323 CTCL. See Cutaneous T-cell lymphoma genetic susceptibility, 321–322 CTLA4, 496 transforming mutation acquisition, 325–326 Cutaneous T-cell lymphoma (CTCL) hematopoiesis disturbances, 321 clinical presentation, 476 malignancy association, 320–321 genetics, 476 Durvalumab, 480 CUX1, 374 DUSP22,56 CXCL12, 4–5, 206, 337, 392 DUX4, 368, 371 CXCR4, 206, 337, 377, 392 DYRK1A, 324 CXCR4, 453 DYRK1A, 367 D E Daratumumab, 488 EATL. See Enteropathy-associated T-cell lymphoma DCAF15, 160–161 EBF1, 52, 364 DDX3X, 452 EBNA2, 187 510 © 2021 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Leukemia and Lymphoma: Molecular and Therapeutic Insights. Click here for more information on how to buy the book.
Load more

Recommended publications
  • O-Glcnacylation Regulates the Stability and Enzymatic Activity of the Histone Methyltransferase EZH2
    O-GlcNAcylation regulates the stability and enzymatic activity of the histone methyltransferase EZH2 Pei-Wen Loa, Jiun-Jie Shieb, Chein-Hung Chena, Chung-Yi Wua, Tsui-Ling Hsua, and Chi-Huey Wonga,1 aGenomics Research Center, Academia Sinica, Taipei 115, Taiwan; and bInstitute of Chemistry, Academia Sinica, Taipei 115, Taiwan Contributed by Chi-Huey Wong, May 16, 2018 (sent for review February 1, 2018; reviewed by Michael D. Burkart, Benjamin G. Davis, and Gerald W. Hart) Protein O-glycosylation by attachment of β-N-acetylglucosamine maintenance and differentiation in embryonic stem cells (14, 15). (GlcNAc) to the Ser or Thr residue is a major posttranslational It was suggested that O-GlcNAcylation might play an important glycosylation event and is often associated with protein folding, role in the regulation of PRC1-mediated gene expression, and stability, and activity. The methylation of histone H3 at Lys-27 along this line the O-GlcNAcylation of EZH2 at S76 in the PRC2 catalyzed by the methyltransferase EZH2 was known to suppress complex was reported to stablize EZH2 in our previous study (16). gene expression and cancer development, and we previously The PRC2 complex is composed of Enhancer of zeste 2 (EZH2), reported that the O-GlcNAcylation of EZH2 at S76 stabilized Suppressor of Zeste 12 (Suz12), Extraembryonic endoderm (EED), EZH2 and facilitated the formation of H3K27me3 to inhibit tumor AE binding protein 2 (AEBP2), and retinoblastoma binding protein suppression. In this study, we employed a fluorescence-based method 4/7 (RBBP4/7) (17, 18). Within the PRC2 complex, EZH2 catalyzes the di- and trimethylation of histone H3 at lysine 27 (K27) to form of sugar labeling combined with mass spectrometry to investigate H3K27me2/3 to regulate embryonic and cancer development EZH2 glycosylation and identified five O-GlcNAcylation sites.
    [Show full text]
  • The Mutational Landscape of Myeloid Leukaemia in Down Syndrome
    cancers Review The Mutational Landscape of Myeloid Leukaemia in Down Syndrome Carini Picardi Morais de Castro 1, Maria Cadefau 1,2 and Sergi Cuartero 1,2,* 1 Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, 08916 Badalona, Spain; [email protected] (C.P.M.d.C); [email protected] (M.C.) 2 Germans Trias i Pujol Research Institute (IGTP), Campus Can Ruti, 08916 Badalona, Spain * Correspondence: [email protected] Simple Summary: Leukaemia occurs when specific mutations promote aberrant transcriptional and proliferation programs, which drive uncontrolled cell division and inhibit the cell’s capacity to differentiate. In this review, we summarize the most frequent genetic lesions found in myeloid leukaemia of Down syndrome, a rare paediatric leukaemia specific to individuals with trisomy 21. The evolution of this disease follows a well-defined sequence of events and represents a unique model to understand how the ordered acquisition of mutations drives malignancy. Abstract: Children with Down syndrome (DS) are particularly prone to haematopoietic disorders. Paediatric myeloid malignancies in DS occur at an unusually high frequency and generally follow a well-defined stepwise clinical evolution. First, the acquisition of mutations in the GATA1 transcription factor gives rise to a transient myeloproliferative disorder (TMD) in DS newborns. While this condition spontaneously resolves in most cases, some clones can acquire additional mutations, which trigger myeloid leukaemia of Down syndrome (ML-DS). These secondary mutations are predominantly found in chromatin and epigenetic regulators—such as cohesin, CTCF or EZH2—and Citation: de Castro, C.P.M.; Cadefau, in signalling mediators of the JAK/STAT and RAS pathways.
    [Show full text]
  • The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiationᰔ† Diego Pasini,1 Adrian P
    MOLECULAR AND CELLULAR BIOLOGY, May 2007, p. 3769–3779 Vol. 27, No. 10 0270-7306/07/$08.00ϩ0 doi:10.1128/MCB.01432-06 Copyright © 2007, American Society for Microbiology. All Rights Reserved. The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiationᰔ† Diego Pasini,1 Adrian P. Bracken,1 Jacob B. Hansen,2 Manuela Capillo,3,4 and Kristian Helin1* Centre for Epigenetics and BRIC, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark1; Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark2; Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy3; and Institute of Molecular Oncology of the Italian Foundation for Cancer Research, Via Adamello 16, 20139 Milan, Italy4 Received 3 August 2006/Returned for modification 10 October 2006/Accepted 22 February 2007 Downloaded from Polycomb group (PcG) proteins form multiprotein complexes, called Polycomb repressive complexes (PRCs). PRC2 contains the PcG proteins EZH2, SUZ12, and EED and represses transcription through methylation of lysine (K) 27 of histone H3 (H3). Suz12 is essential for PRC2 activity and its inactivation results in early lethality of mouse embryos. Here, we demonstrate that Suz12؊/؊ mouse embryonic stem (ES) cells can be established and expanded in tissue culture. The Suz12؊/؊ ES cells are characterized by global loss of H3K27 trimethylation (H3K27me3) and higher expression levels of differentiation-specific genes. Moreover, Suz12؊/؊ ES cells are impaired in proper differentiation, resulting in a lack of repression of ES cell markers as well as activation of differentiation-specific genes. Finally, we demonstrate that the PcGs are actively recruited to several genes during ES cell differentiation, which despite an increase in H3K27me3 levels is not always http://mcb.asm.org/ sufficient to prevent transcriptional activation.
    [Show full text]
  • Automethylation of PRC2 Promotes H3K27 Methylation and Is Impaired in H3K27M Pediatric Glioma
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma Chul-Hwan Lee,1,2,7 Jia-Ray Yu,1,2,7 Jeffrey Granat,1,2,7 Ricardo Saldaña-Meyer,1,2 Joshua Andrade,3 Gary LeRoy,1,2 Ying Jin,4 Peder Lund,5 James M. Stafford,1,2,6 Benjamin A. Garcia,5 Beatrix Ueberheide,3 and Danny Reinberg1,2 1Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA; 3Proteomics Laboratory, New York University School of Medicine, New York, New York 10016, USA; 4Shared Bioinformatics Core, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; 5Department of Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA The histone methyltransferase activity of PRC2 is central to the formation of H3K27me3-decorated facultative heterochromatin and gene silencing. In addition, PRC2 has been shown to automethylate its core subunits, EZH1/ EZH2 and SUZ12. Here, we identify the lysine residues at which EZH1/EZH2 are automethylated with EZH2-K510 and EZH2-K514 being the major such sites in vivo. Automethylated EZH2/PRC2 exhibits a higher level of histone methyltransferase activity and is required for attaining proper cellular levels of H3K27me3. While occurring inde- pendently of PRC2 recruitment to chromatin, automethylation promotes PRC2 accessibility to the histone H3 tail. Intriguingly, EZH2 automethylation is significantly reduced in diffuse intrinsic pontine glioma (DIPG) cells that carry a lysine-to-methionine substitution in histone H3 (H3K27M), but not in cells that carry either EZH2 or EED mutants that abrogate PRC2 allosteric activation, indicating that H3K27M impairs the intrinsic activity of PRC2.
    [Show full text]
  • The EZH1–SUZ12 Complex Positively Regulates the Transcription of NF-Κb
    © 2016. Published by The Company of Biologists Ltd | Journal of Cell Science (2016) 129, 2343-2353 doi:10.1242/jcs.185546 RESEARCH ARTICLE The EZH1–SUZ12 complex positively regulates the transcription of NF-κB target genes through interaction with UXT Shuai-Kun Su, Chun-Yuan Li, Pin-Ji Lei, Xiang Wang, Quan-Yi Zhao, Yang Cai, Zhen Wang, Lianyun Li* and Min Wu* ABSTRACT zeste 2 polycomb repressive complex 2 subunit (EZH2) (Shen et al., Drosophila Unlike other members of the polycomb group protein family, EZH1 2008). EZH2 mimics the function of E(Z) in and is the has been shown to positively associate with active transcription on a main methyltransferase for H3K27 in mammalian cells (Shen et al., genome-wide scale. However, the underlying mechanism for this 2008). However, controversial reports exist about EZH1, which behavior still remains elusive. Here, we report that EZH1 physically means its activities have been a puzzle for a long time. Compared interacts with UXT, a small chaperon-like transcription co-activator. with EZH2, EZH1 has lower enzymatic activity, suggesting it might UXT specifically interacts with EZH1 and SUZ12, but not EED. have distinct functions (Margueron et al., 2008). Several groups Similar to upon knockdown of UXT, knockdown of EZH1 or SUZ12 reported that EZH1 methylates histone H3K27 and compensates for through RNA interference in the cell impairs the transcriptional the functions of EZH2 upon its absence (Bae et al., 2015; Hidalgo activation of nuclear factor (NF)-κB target genes induced by TNFα. et al., 2012; Shen et al., 2008). Recently, Mousavi et al.
    [Show full text]
  • Alu Elements in ANRIL Non-Coding RNA at Chromosome 9P21 Modulate Atherogenic Cell Functions Through Trans-Regulation of Gene Networks
    Alu Elements in ANRIL Non-Coding RNA at Chromosome 9p21 Modulate Atherogenic Cell Functions through Trans-Regulation of Gene Networks Lesca M. Holdt1,2,3, Steve Hoffmann1,4, Kristina Sass2, David Langenberger1,4, Markus Scholz1,5, Knut Krohn1,6, Knut Finstermeier1,2, Anika Stahringer2,3, Wolfgang Wilfert2,3, Frank Beutner1,2,7, Stephan Gielen1,7, Gerhard Schuler1,7, Gabor Ga¨bel8, Hendrik Bergert8, Ingo Bechmann9, Peter F. Stadler1,4,10,11, Joachim Thiery1,2, Daniel Teupser1,2,3* 1 LIFE – Leipzig Research Center for Civilization Diseases, Universita¨t Leipzig, Leipzig, Germany, 2 Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany, 3 Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, Munich, Germany, 4 Transcriptome Bioinformatics Group and Interdisciplinary Centre for Bioinformatics, University Leipzig, Leipzig, Germany, 5 Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany, 6 Interdisciplinary Center for Clinical Research, University Leipzig, Leipzig, Germany, 7 Department of Internal Medicine/Cardiology, Heart Center, University Leipzig, Leipzig, Germany, 8 Department of General, Thoracic, and Vascular Surgery, University Dresden, Dresden, Germany, 9 Institute of Anatomy, University Leipzig, Leipzig, Germany, 10 Max Planck Institute for Mathematics in the Sciences, Leipzig, Germany, 11 Santa Fe Institute, Santa Fe, New Mexico, United States of America Abstract The chromosome 9p21 (Chr9p21) locus of coronary artery disease has been identified in the first surge of genome-wide association and is the strongest genetic factor of atherosclerosis known today. Chr9p21 encodes the long non-coding RNA (ncRNA) antisense non-coding RNA in the INK4 locus (ANRIL). ANRIL expression is associated with the Chr9p21 genotype and correlated with atherosclerosis severity.
    [Show full text]
  • A High-Density Map for Navigating the Human Polycomb Complexome
    Resource A High-Density Map for Navigating the Human Polycomb Complexome Graphical Abstract Authors Simon Hauri, Federico Comoglio, Makiko Seimiya, ..., Renato Paro, Matthias Gstaiger, Christian Beisel Correspondence [email protected] (M.G.), [email protected] (C.B.) In Brief Polycomb group (PcG) proteins mediate gene silencing and epigenetic memory in higher eukaryotes. By systematically mapping the human PcG complexome, Hauri et al. resolve Polycomb subcomplexes at high resolution and identify two human PRC2 and two PR- DUB complexes. Furthermore, genomic profiling reveals segregation of PRC1 and PR-DUB target genes. Highlights Accession Numbers d 1,400 high-confidence interactions reveal the modular GSE51673 organization of human PcG proteins d Detailed dissection of PRC1 and PRC2 subcomplexes d Two human PR-DUB complexes contain the glycosyltransferase OGT1 d PR-DUB and PRC1 bind largely distinct sets of target genes Hauri et al., 2016, Cell Reports 17, 583–595 October 4, 2016 ª 2016 The Authors. http://dx.doi.org/10.1016/j.celrep.2016.08.096 Cell Reports Resource A High-Density Map for Navigating the Human Polycomb Complexome Simon Hauri,1,2,7,8 Federico Comoglio,3,7,9 Makiko Seimiya,3 Moritz Gerstung,3,10 Timo Glatter,1,11 Klaus Hansen,4 Ruedi Aebersold,1,5 Renato Paro,3,6 Matthias Gstaiger,1,2,* and Christian Beisel3,12,* 1Department of Biology, Institute of Molecular Systems Biology, ETH Zurich,€ 8093 Zurich,€ Switzerland 2Competence Center Personalized Medicine UZH/ETH, 8044 Zurich,€ Switzerland 3Department
    [Show full text]
  • Genome-Wide Remodeling of the Epigenetic Landscape During
    Genome-wide remodeling of the epigenetic landscape PNAS PLUS during myogenic differentiation Patrik Aspa,1,2, Roy Bluma,1, Vasupradha Vethanthama, Fabio Parisib,c, Mariann Micsinaib,c, Jemmie Chenga, Christopher Bowmana, Yuval Klugerb,c, and Brian David Dynlachta,3 aDepartment of Pathology and Cancer Institute, New York University School of Medicine, 522 First Avenue, Smilow Research Building 1104, New York, NY 10016; bNew York University Center for Health Informatics and Bioinformatics, 550 First Ave, New York, NY 10016; and cDepartment of Pathology and Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520 Edited* by Robert Tjian, Howard Hughes Medical Institute, Chevy Chase, MD, and approved April 4, 2011 (received for review February 9, 2011) We have examined changes in the chromatin landscape during gene activation or repression, respectively, in accordance with the muscle differentiation by mapping the genome-wide location of lineage specified by the marked gene. This mechanism has been ten key histone marks and transcription factors in mouse myo- shown to be critical for commitment to neuronal and other fates blasts and terminally differentiated myotubes, providing an excep- (4). However, despite our understanding of the role of these “ ” tionally rich dataset that has enabled discovery of key epigenetic modifications as on/off switches, the epigenetic landscape is changes underlying myogenesis. Using this compendium, we considerably more nuanced as a result of the large number of focused on a well-known repressive mark, histone H3 lysine 27 tri- possible permutations specified by modifications of all four methylation, and identified novel regulatory elements flanking the histones that dictate both dynamic and irreversible changes in chromatin.
    [Show full text]
  • TERRA Regulate the Transcriptional Landscape of Pluripotent Cells
    RESEARCH ARTICLE TERRA regulate the transcriptional landscape of pluripotent cells through TRF1-dependent recruitment of PRC2 Rosa Marı´aMario´ n1†, Juan J Montero1†, Isabel Lo´ pez de Silanes1, Osvaldo Gran˜ a-Castro2, Paula Martı´nez1, Stefan Schoeftner1‡§, Jose´ Alejandro Palacios-Fa´ brega1#, Maria A Blasco1* 1Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain; 2Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain Abstract The mechanisms that regulate pluripotency are still largely unknown. Here, we show that Telomere Repeat Binding Factor 1 (TRF1), a component of the shelterin complex, regulates the genome-wide binding of polycomb and polycomb H3K27me3 repressive marks to pluripotency genes, thereby exerting vast epigenetic changes that contribute to the maintenance of mouse ES *For correspondence: cells in a naı¨ve state. We further show that TRF1 mediates these effects by regulating TERRA, the [email protected] lncRNAs transcribed from telomeres. We find that TERRAs are enriched at polycomb and stem cell † These authors contributed genes in pluripotent cells and that TRF1 abrogation results in increased TERRA levels and in higher equally to this work TERRA binding to those genes, coincidental with the induction of cell-fate programs and the loss of Present address: ‡Genomic the naı¨ve state. These results are consistent with a model in which TRF1-dependent changes in Stability Unit, Laboratorio TERRA levels modulate polycomb
    [Show full text]
  • Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase
    BASIC RESEARCH www.jasn.org Renoprotective Effect of Combined Inhibition of Angiotensin-Converting Enzyme and Histone Deacetylase † ‡ Yifei Zhong,* Edward Y. Chen, § Ruijie Liu,*¶ Peter Y. Chuang,* Sandeep K. Mallipattu,* ‡ ‡ † | ‡ Christopher M. Tan, § Neil R. Clark, § Yueyi Deng, Paul E. Klotman, Avi Ma’ayan, § and ‡ John Cijiang He* ¶ *Department of Medicine, Mount Sinai School of Medicine, New York, New York; †Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; ‡Department of Pharmacology and Systems Therapeutics and §Systems Biology Center New York, Mount Sinai School of Medicine, New York, New York; |Baylor College of Medicine, Houston, Texas; and ¶Renal Section, James J. Peters Veterans Affairs Medical Center, New York, New York ABSTRACT The Connectivity Map database contains microarray signatures of gene expression derived from approximately 6000 experiments that examined the effects of approximately 1300 single drugs on several human cancer cell lines. We used these data to prioritize pairs of drugs expected to reverse the changes in gene expression observed in the kidneys of a mouse model of HIV-associated nephropathy (Tg26 mice). We predicted that the combination of an angiotensin-converting enzyme (ACE) inhibitor and a histone deacetylase inhibitor would maximally reverse the disease-associated expression of genes in the kidneys of these mice. Testing the combination of these inhibitors in Tg26 mice revealed an additive renoprotective effect, as suggested by reduction of proteinuria, improvement of renal function, and attenuation of kidney injury. Furthermore, we observed the predicted treatment-associated changes in the expression of selected genes and pathway components. In summary, these data suggest that the combination of an ACE inhibitor and a histone deacetylase inhibitor could have therapeutic potential for various kidney diseases.
    [Show full text]
  • Clinical Impact of Genomic Characterization of 15 Patients with Acute Megakaryoblastic Leukemia Related Malignancies
    Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia related malignancies Emilie Lalonde1, Stefan Rentas1, Gerald Wertheim2, Lea Surrey2, Fumin Lin1, Xiaonan Zhao1, Amrom Obstfeld1, Richard Aplenc3, Minjie Luo1, and Marilyn Li1 1The Children's Hospital of Philadelphia 2Children's Hospital of Philadelphia 3The Children's Hospital of Philadelphia July 20, 2020 Abstract Background: Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia but is ~500 times more likely to develop in children with Down syndrome (DS) thro INTRODUCTION Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML), defined by the presence of at least 50% of blasts from the megakaryocytic lineage, and patients often present with thrombocytopenia or thrombocytosis. Other clinical features include dysplastic neutrophils, erythroid cells, and germ cell tumors in young men. AMKL is typically observed in children, accounting for 4-15% of AML cases, compared to <1% of adult patients. A diagnosis of AMKL can be made if the pathognomonic t(1;22)(p13.3;q13.3) translocation is observed, resulting in a RBM15-MKL1 gene fusion, or by pathological assessment of bone marrow as described above. However, recent studies have shown that AMKL is genetically heterogeneous with distinct sub-groups based on cytogenetic and molecular alterations.1,2 Children with Down syndrome (DS) have an estimated 150- to 500-fold increased risk of AMKL compared to children without DS.3,4 In uteroGATA1 mutations
    [Show full text]
  • Dedifferentiation Orchestrated Through Remodeling of the Chromatin Landscape Defines PSEN1 Mutation-Induced Alzheimer’S Disease
    bioRxiv preprint doi: https://doi.org/10.1101/531202; this version posted January 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dedifferentiation orchestrated through remodeling of the chromatin landscape defines PSEN1 mutation-induced Alzheimer’s Disease Andrew B. Caldwell1, Qing Liu2, Gary P. Schroth3, Rudolph E. Tanzi4, Douglas R. Galasko2, Shauna H. Yuan2, Steven L. Wagner2,5, & Shankar Subramaniam1,6,7,8* 1Department of Bioengineering, University of California, San Diego, La Jolla, California, USA. 2Department of Neurosciences, University of California, San Diego, La Jolla, California, USA. 3Illumina, Inc., San Diego, California, USA. 4Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, USA. 5VA San Diego Healthcare System, La Jolla, California, USA. 6Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California, USA. 7Department of Nanoengineering, University of California, San Diego, La Jolla, California, USA. 8Department of Computer Science and Engineering, University of California, San Diego, La Jolla, California, USA. Abstract Early-Onset Familial Alzheimer’s Disease (EOFAD) is a dominantly inherited neurodegenerative disorder elicited by mutations in the PSEN1, PSEN2, and APP genes1. Hallmark pathological changes and symptoms observed, namely the accumulation of misfolded Amyloid-β (Aβ) in plaques and Tau aggregates in neurofibrillary tangles associated with memory loss and cognitive decline, are understood to be temporally accelerated manifestations of the more common sporadic Late-Onset Alzheimer’s Disease. The complete penetrance of EOFAD-causing mutations has allowed for experimental models which have proven integral to the overall understanding of AD2.
    [Show full text]